☰

Norman W Barton, MD, PhD

Affiliations: 
2013-2018 Neuroscience Shire 
 2018- Rare Diseases Takeda 
Area:
Leukodystrophies, Neurochemistry
Google:
"Norman Barton"
Mean distance: (not calculated yet)
 
Tree Publications Grants Similar researchers PubMed Report error

Parents

Sign in to add mentor
Fred Plum post-doc 1976-1980 Cornell Medical College
Jerome Posner post-doc 1976-1980 Cornell Medical College
Roscoe O. Brady research scientist 1982-1996 National Institutes of Health-NINDS

Children

Sign in to add trainee
Joseph J Higgins post-doc 1990-1993 National Institutes of Health-NINDS
C.J. Malanga research scientist 2021-2022 Takeda Pharmaceuticals

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Farah MH, Dali CÍ, Groeschel S, et al. (2023) Effects of sulfatide on peripheral nerves in metachromatic leukodystrophy. Annals of Clinical and Translational Neurology
Mistry PK, Lopez G, Schiffmann R, et al. (2016) Gaucher disease circa 2016: Progress and ongoing challenges. Molecular Genetics and Metabolism
Desnick RJ, Barton NW, Furbish S, et al. (2016) Roscoe Owen Brady, MD: Remembrances of co-investigators and colleagues. Molecular Genetics and Metabolism
Ben Turkia H, Gonzalez DE, Barton NW, et al. (2013) Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. American Journal of Hematology. 88: 179-84
Gonzalez DE, Turkia HB, Lukina EA, et al. (2013) Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study. American Journal of Hematology. 88: 166-71
Mehta A, Turkia HB, Gonzalez D, et al. (2011) Two-Year Safety and Tolerability of Velaglucerase Alfa in Patients with Type 1 Gaucher Disease, Including Patients Switched From Imiglucerase: Phase III Trial HGT-GCB-039 and Extension, Blood. 118: 3214-3214
Luciano CA, Russell JW, Banerjee TK, et al. (2002) Physiological characterization of neuropathy in Fabry's disease. Muscle & Nerve. 26: 622-9
Schiffmann R, Mankin H, Dambrosia JM, et al. (2002) Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy Blood Cells, Molecules, and Diseases. 28: 288-296
Altarescu G, Hill S, Wiggs E, et al. (2001) The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. The Journal of Pediatrics. 138: 539-47
Altarescu G, Schiffmann R, Parker CC, et al. (2000) Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease. Blood Cells, Molecules & Diseases. 26: 285-90
See more...